Pharma BD Deal Intelligence
Millennium paid ~$2B in stock for COR's cardiovascular franchise, then sold the core asset (Integrilin) for ~$35.5M three-and-a-half years later and pivoted the company entirely to oncology.
Full analysis, sources & comparables →"This merger will create a leading biopharmaceutical company with multiple products on the market, nine candidate products in human clinical trials, four…
WSJ, Boston Globe, NY Times and Dow Jones all reported analyst skepticism about the deal as Millennium's stock sold off and Integrilin sales were perceived to…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Stock-for-stock; 0.9873 Millennium shares per COR share. Brought in Integrilin (eptifibatide) cardiovascular franchise. Closed 2002-02-12.
Millennium paid ~$2B in stock for COR's cardiovascular franchise, then sold the core asset (Integrilin) for ~$35.5M three-and-a-half years later and pivoted the company entirely to oncology.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Millennium Pharmaceuticals / COR Therapeutics Inc. (this deal) | 2001 | $2.0B | 21 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals